Lates News

Every Investment AI Flash, Open Source Securities released a research report on February 7, giving DeYuan Pharmaceutical (920735.SH) a "buy" rating. The reasons for the rating include: 1) full efforts to expand the market, sales of "Fu Rutong" and "Bo Kaiqing" increasing, supplying the tenth batch of centralized procurement products; 2) by 2025, obtaining registration approvals for 8 varieties of drugs, with the adaptation indication of DYX116 for hypoglycemia undergoing phase I clinical trials. (Daily Economic News)